ZEGERID competes in a crowded category against major players such as Nexium and Prevacid. The goal of the banner campaign was to test the effectiveness of online advertising as a channel to reach and influence the PCP audience, especially those not detailed by sales reps (Family Practice and Internists). Compass Healthcare Communications designed, developed, and measured ads that were created to increase targeted awareness of ZEGERID and its unique benefits among PPIs. Pre and post surveys were used to determine the success of the banners. The campaign significantly increased awareness among the target audience. For the entire survey population (GIs, FPs, and IMs) awareness increased from 52% to 76%. FPs and IMs, the primary targets since they are not detailed by sales reps, saw the most positive results.
Contributors:
COMPASS HEALTHCARE COMMUNICATI
Location: USA